Table 3 Adverse events during treatment phases
From: Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial
Patient | Adverse events | Treatment sequence | Treatment phase |
|---|---|---|---|
1 | Fast progressing muscle weakness, back pain, weight gain (4 kg), acne, Cushing | P/D | Deflazacort |
2 | None | D/P | |
3 | Fast progressing muscle weakness, acne, hypertonia, fatigue, tachycardia, tremor | P/D | Deflazacort |
4 | Fast progressing muscle weakness, mainly in head lifting | D/P | Deflazacort |
5 | Hypertonia | D/P | Deflazacort |
6 | Fast progressing muscle weakness, weight gain, Cushing | P/D | Deflazacort |
7 | Weight gain | D/P | Deflazacort |
8 | None | D/P | |
9 | None | P/D | |
10 | Hair loss, GIT symptoms | P/D | Deflazacort |
11 | None | P/D | |
12 | Weight gain (5 kg), acne, GIT symptoms | D/P | Deflazacort |
13 | GIT symptoms | P/D | Placebo |
14 | None | P/D | |
15 | Fast progressing muscle weakness, head ache, sleep disturbances | D/P | Deflazacort |
16 | None | D/P | |
17 | None | P/D | |
18 | GIT symptoms, acne | D/P | Deflazacort |
19 | Weight gain | P/D | Placebo |
20 | None | P/D | |
21 | None | P/D | |
22 | Fast progressing muscle weakness | D/P | Deflazacort |
23 | None | D/P |